CANDEL THERAPEUTICS, INC. Research and Development Expense
CANDEL THERAPEUTICS, INC. (CADL) reported Research and Development Expense of $19.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $19.80M, a 183.24% increase year-over-year.
- CANDEL THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $9.84M, a 145.02% increase year-over-year.
- CANDEL THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $11.03M, a 128.94% increase year-over-year.
- CANDEL THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $8.46M, a 56.22% increase year-over-year.
- CANDEL THERAPEUTICS, INC. research and development expense for fiscal 2025 was $30.50M, a 57.90% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. research and development expense for fiscal 2024 was $19.31M, a 21.19% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. research and development expense for fiscal 2023 was $24.51M, a 17.89% increase from fiscal 2022.
- CANDEL THERAPEUTICS, INC. research and development expense for fiscal 2022 was $20.79M, a 36.95% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.80M 10-Q · filed 2026-08-13 | $29.64M 10-Q · filed 2026-08-13 | $40.67M derived: sum of 3 quarters · filed 2026-08-13 | $49.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $9.84M 10-Q · filed 2026-05-14 | $20.87M derived: sum of 2 quarters · filed 2026-05-14 | $29.33M derived: sum of 3 quarters · filed 2026-05-14 | $36.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $11.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $19.49M derived: sum of 2 quarters · filed 2026-03-12 | $26.48M derived: sum of 3 quarters · filed 2026-08-13 | $30.50M 10-K · filed 2026-03-12 |
| 2025-09-30 | $8.46M 10-Q · filed 2025-11-13 | $15.45M derived: sum of 2 quarters · filed 2026-08-13 | $19.47M 10-Q · filed 2025-11-13 | $24.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.99M 10-Q · filed 2026-08-13 | $11.01M 10-Q · filed 2026-08-13 | $15.82M derived: sum of 3 quarters · filed 2026-08-13 | $21.24M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $4.02M 10-Q · filed 2026-05-14 | $8.83M derived: sum of 2 quarters · filed 2026-05-14 | $14.25M derived: sum of 3 quarters · filed 2026-05-14 | $19.23M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $10.23M derived: sum of 2 quarters · filed 2026-03-12 | $15.21M derived: sum of 3 quarters · filed 2026-03-12 | $19.31M 10-K · filed 2026-03-12 |
| 2024-09-30 | $5.42M 10-Q · filed 2025-11-13 | $10.39M derived: sum of 2 quarters · filed 2025-11-13 | $14.50M 10-Q · filed 2025-11-13 | $21.75M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $4.98M 10-Q · filed 2025-08-14 | $9.08M 10-Q · filed 2025-08-14 | $16.34M derived: sum of 3 quarters · filed 2025-08-14 | $22.18M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $4.10M 10-Q · filed 2025-05-13 | $11.36M derived: sum of 2 quarters · filed 2025-05-13 | $17.20M derived: sum of 3 quarters · filed 2025-05-13 | $23.14M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $13.10M derived: sum of 2 quarters · filed 2025-03-13 | $19.04M derived: sum of 3 quarters · filed 2025-03-13 | $24.51M 10-K · filed 2025-03-13 |
| 2023-09-30 | $5.84M 10-Q · filed 2024-11-14 | $11.78M derived: sum of 2 quarters · filed 2024-11-14 | $17.25M 10-Q · filed 2024-11-14 | $22.22M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $5.93M 10-Q · filed 2024-08-13 | $11.40M 10-Q · filed 2024-08-13 | $16.38M derived: sum of 3 quarters · filed 2024-08-13 | $21.75M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $5.47M 10-Q · filed 2024-05-14 | $10.44M derived: sum of 2 quarters · filed 2024-05-14 | $15.82M derived: sum of 3 quarters · filed 2024-05-14 | $20.84M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $4.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $10.35M derived: sum of 2 quarters · filed 2024-03-28 | $15.37M derived: sum of 3 quarters · filed 2024-03-28 | $20.79M 10-K · filed 2024-03-28 |
| 2022-09-30 | $5.38M 10-Q · filed 2023-11-09 | $10.40M derived: sum of 2 quarters · filed 2023-11-09 | $15.81M 10-Q · filed 2023-11-09 | $19.67M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.02M 10-Q · filed 2023-08-10 | $10.44M 10-Q · filed 2023-08-10 | $14.29M derived: sum of 3 quarters · filed 2023-08-10 | $19.56M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $5.42M 10-Q · filed 2023-05-11 | $9.27M derived: sum of 2 quarters · filed 2023-05-11 | $14.54M derived: sum of 3 quarters · filed 2023-05-11 | $17.83M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $9.12M derived: sum of 2 quarters · filed 2023-03-30 | $12.41M derived: sum of 3 quarters · filed 2023-03-30 | $15.18M 10-K · filed 2023-03-30 |
| 2021-09-30 | $5.26M 10-Q · filed 2022-11-10 | $8.56M derived: sum of 2 quarters · filed 2022-11-10 | $11.32M 10-Q · filed 2022-11-10 | $14.84M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.29M 10-Q · filed 2022-08-05 | $6.05M 10-Q · filed 2022-08-05 | $9.58M derived: sum of 3 quarters · filed 2022-08-05 | $11.39M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $2.75M 10-Q · filed 2022-05-12 | $6.29M derived: sum of 2 quarters · filed 2022-05-12 | $8.10M derived: sum of 3 quarters · filed 2022-05-12 | $9.89M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $5.35M derived: sum of 2 quarters · filed 2022-03-29 | $7.14M derived: sum of 3 quarters · filed 2022-03-29 | $8.75M 10-K · filed 2022-03-29 |
| 2020-09-30 | $1.81M 10-Q · filed 2021-11-12 | $3.61M derived: sum of 2 quarters · filed 2021-11-12 | $5.22M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.79M 10-Q · filed 2021-09-08 | $3.42M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |